Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as filings are not required immediately at the end of each quarter. Here’s a review of Q2 2025 activity… Psychedelic drug developers’ spend on federal lobbying in Q2’25 looked very similar to that seen in the first quarter…
